A Phase 1 interventional study of [14C] MK-5475 in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-29.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to understand how radiolabeled MK-5475 administered intravenously (IV) is taken up by the body, broken down and then removed from the body in healthy male participants. The study also aims to understand how much of the compound is broken down and how much leaves the body unchanged.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
\[14C\] MK-5475 is administered as single IV bolus dose of 100μg on Day 1.
Drug: [14C] MK-5475
\[14C\] MK-5475 is administered as a single IV bolus dose in healthy male participants on Day 1.
Amount Excreted in Urine (Aeu)
Amount of \[14C\]MK-5475 and its metabolites excreted in urine (Aeu) derived from urine collections at each sampling interval.
Time frame: At designated time points (Up to ~ 23 days)
Cumulative Aeu
Cumulative amount of \[14C\] MK-5475 and its metabolites excreted in urine derived from urine collections at each sampling interval
Time frame: At designated time points (Up to ~ 23 days)
Percentage Excreted in Urine (feu)
Percentage of \[14C\]MK-5475 and its metabolites excreted in urine derived from urine collections at each sampling interval.
Time frame: At designated time points (Up to ~ 23 days)
Cumulative feu
Cumulative percentage of \[14C\]MK-5475 and its metabolites excreted in urine derived from urine collections at each sampling interval.
Time frame: At designated time points (Up to ~ 23 days)
Amount Excreted in Feces (Aef)
Amount of \[14C\]MK-5475 and its metabolites excreted in feces derived from feces collections at each sampling interval.
Time frame: At designated time points (Up to ~ 23 days)
Cumulative Aef
Cumulative amount of \[14C\]MK-5475 and its metabolites excreted in feces derived from feces collections at each sampling interval.
Time frame: At designated time points (Up to ~ 23 days)
Cumulative Fef
Cumulative percentage of \[14C\]MK-5475 and its metabolites excreted in feces derived from feces collections at each sampling interval.
Time frame: At designated time points (Up to ~ 23 days)
AUC0-t
Area under concentration time curve (AUC) from time zero to the last quantifiable concentration derived from the whole blood and plasma concentration-time profiles following IV administration of \[14C\]MK-5475.
Time frame: At designated time points (Up to ~ 23 days)
AUC0-infinity
AUC from time zero extrapolated to infinity derived from the whole blood and plasma concentration-time profiles following IV administration of \[14C\]MK-5475.
Time frame: At designated time points (Up to ~ 23 days)
Maximum Plasma Concentration (Cmax)
Cmax is the measure of the maximum amount of \[14C\]MK-5475 in the plasma after the dose is given.
Time frame: At designated time points (Up to ~ 23 days)
Half-life t1/2
T1/2 is the time required for \[14C\]MK-5475 concentration in the plasma to decrease by 50%.
Time frame: At designated time points (Up to ~ 23 days)
Time to Maximum Plasma Concentration (Tmax),
Tmax is a measure of the time to reach the maximum concentration in the plasma after the \[14C\]MK-5475 dose.
Time frame: At designated time points (Up to ~ 23 days)
Apparent Total Clearance (CL; MK-5475 only)
CL is defined as apparent total clearance of \[14C\]MK-5475 from plasma after IV administration
Time frame: At designated time points (Up to ~ 23 days)
Apparent Volume of Distribution (Vz; MK-5475 only)
Vz is defined as apparent volume of distribution of \[14C\]MK-5475 during terminal phase after IV administration.
Time frame: At designated time points (Up to ~ 23 days)
AUC0-infinity Plasma [14C]MK-5475/Total Radioactivity Ratio
AUC time zero to infinity (0-∞) of \[14C\]MK-5475 in plasma/AUC0-∞ of total radioactivity in plasma.
Time frame: At designated time points (Up to ~ 23 days)
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
Time frame: Up to ~ 30 days
Number of Participants Who Discontinue Study Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study due to an AE will be reported.
Time frame: Up to ~ 30 days
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Aug 2022 to primary completion in Sep 2022, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Frespaciguat